커큐민 관련 크론병
C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.제한적인 RCT 근거입니다. CDAI 점수에서 일부 개선이 있었으나 결과가 일관되지 않습니다. 크론병보다 UC에서 더 나은 근거가 있습니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dcurcumin\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
제한적인 RCT 근거입니다. CDAI 점수에서 일부 개선이 있었으나 결과가 일관되지 않습니다. 크론병보다 UC에서 더 나은 근거가 있습니다.
Key Study Findings
Meta-Analysis
n=2260
Comparative Efficacy of Medical Therapies in Reducing the Risk of Postoperative Recurrence in Crohn's Disease: …
Dose: None
vs: placebo or other medical therapies
Outcome: endoscopic recurrence (Rutgeerts score >= i2) at 6 …
효과: adalimumab vs thiopurines OR 0.33 (95% CI 0.12-0.91); adalimumab vs vitamin D OR 0.07 (95% CI 0.01-0
None
대상 집단: patients with Crohn's disease post-surgery from 42 studies (38 RCTs)
Meta-Analysis
Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of …
Dose: Varying dosages
vs: Placebo
Outcome: Clinical remission and response in UC
효과: None
None
대상 집단: UC and CD patients (13 RCTs)
Systematic Review
[Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review].
Dose: Peppermint oil, STW-5, psyllium, others
vs: Standard care or placebo
Outcome: Symptom improvement in GI diseases
효과: None
None
대상 집단: Patients with gastroenterological diseases
Review
Use of curcumin and its nanopreparations in the treatment of inflammatory bowel disease.
Dose: Curcumin nanoformulations
vs: None
Outcome: IBD symptom improvement
효과: None
None
대상 집단: IBD patients (preclinical/clinical review)
Review
Phytochemicals and Regulation of NF-kB in Inflammatory Bowel Diseases: An Overview of In Vitro and …
Dose: Various phytochemicals
vs: None
Outcome: NF-kB regulation in IBD
효과: None
None
대상 집단: In vitro and in vivo IBD models
Meta-Analysis
Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune Diseases: A …
Dose: None
vs: Placebo or standard care
Outcome: Clinical/laboratory outcomes in autoimmune diseases
효과: None
None
대상 집단: Patients with 10 types of autoimmune diseases
Key Statistics
3
연구
200
참여자
↔
Mixed
C
등급
Referenced Papers
Inflammatory bowel diseases
2026
Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials.
Systematic Review
Frontiers in nutrition
2025
8 인용
[Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review].
Systematic Review
Zeitschrift fur Gastroenterologie
2024
3 인용
World journal of …
2024
Metabolites
2023
134 인용
Frontiers in immunology
2022
68 인용
Molecules (Basel, Switzerland)
2021
85 인용
Effects of the Use of Curcumin on Ulcerative Colitis and Crohn's Disease: A Systematic Review.
Meta-Analysis
Journal of medicinal …
2021
52 인용
United European gastroenterology …
2021
41 인용
European journal of …
2021
40 인용
A Systematic Review of the Clinical Use of Curcumin for the Management of Gastrointestinal Diseases.
Systematic Review
Advances in experimental …
2021
8 인용
Journal of Crohn's …
2020
71 인용
Clinical gastroenterology and …
2020
49 인용
The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.
Systematic Review
Nutrients
2020
48 인용
Nutrients
2020
30 인용
Digestive and liver …
2020
14 인용
Medicine
2020
4 인용
International journal of …
2019
137 인용
Critical reviews in …
2019
48 인용
Journal of medicinal …
2019
17 인용
Current opinion in …
2019
5 인용
Gastroenterology clinics of …
2018
67 인용
Macromolecular bioscience
2018
13 인용
Gastroenterology
2017
335 인용
Medical principles and …
2017
45 인용
JPEN. Journal of …
2017
24 인용
Comparison of remicade to curcumin for the treatment of Crohn's disease: A systematic review.
Systematic Review
Complementary therapies in …
2017
23 인용
The Medical clinics …
2017
9 인용
Ugeskrift for laeger
2017
Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis.
Review
Current pharmaceutical design
2016
32 인용
Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases.
Systematic Review
Journal of Crohn's …
2015
184 인용
Annals of gastroenterology
2015
135 인용
Molecules (Basel, Switzerland)
2014
122 인용
Experimental cell research
2014
16 인용
The AAPS journal
2013
1866 인용
Alimentary pharmacology & …
2013
128 인용
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Other
Journal of pediatric …
2013
103 인용
Nature reviews. Gastroenterology …
2013
47 인용
Food & function
2012
151 인용
Journal of the …
2009
24 인용
Molecular nutrition & …
2008
67 인용
Revista de gastroenterologia …
2008
2 인용
Digestive diseases and …
2005
461 인용
Bioinformatics (Oxford, England)
2004
149 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 500-1,500 mg/day with piperine (black pepper extract) for absorption
- ibssupport:
- 500-1,000 mg/day
- ucmaintenance:
- 2,000 mg/day (1 g twice daily) as adjunct to mesalamine
상한량: Well-tolerated up to 8 g/day in clinical trials (most studies use 1-2 g/day)
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | 2260 |
| Varying dosages | -- | Positive | -- |
| Peppermint oil, STW-5, psyllium, others | -- | Positive | -- |
| Curcumin nanoformulations | -- | Positive | -- |
| Various phytochemicals | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
권장 복용 시간: With meals containing fat and black pepper for enhanced absorption
Safety & Side Effects
보고된 부작용
- ⚠ GI discomfort (nausea, diarrhea, abdominal pain) at high doses
- ⚠ Yellow staining of skin/teeth with topical/oral contact
- ⚠ Increased gallbladder contractions (avoid with gallstones or bile duct obstruction)
- ⚠ Iron chelation (may reduce iron absorption at very high doses)
알려진 상호작용
- ● Anticoagulants (curcumin has antiplatelet properties; may increase bleeding risk)
- ● Chemotherapy agents (curcumin may alter drug metabolism via CYP enzyme inhibition)
- ● Sulfasalazine (additive anti-inflammatory effect — may be beneficial in IBD)
- ● Iron supplements (curcumin may chelate iron; space dosing)
- ● Piperine/black pepper (enhances curcumin bioavailability by 2,000% — commonly co-administered)
일일 최대 섭취 허용량: Well-tolerated up to 8 g/day in clinical trials (most studies use 1-2 g/day)
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 커큐민 help with 크론병?
Based on 3 studies with 200 participants, there is limited but promising evidence that 커큐민 may support 크론병 management. Our evidence grade is C (Some Evidence).
How much 커큐민 should I take for 크론병?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day with piperine (black pepper extract) for absorption. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 커큐민?
Reported side effects may include GI discomfort (nausea, diarrhea, abdominal pain) at high doses, Yellow staining of skin/teeth with topical/oral contact, Increased gallbladder contractions (avoid with gallstones or bile duct obstruction), Iron chelation (may reduce iron absorption at very high doses). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 커큐민 and 크론병?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 200 total participants. The overall direction of effect is mixed.
Related Evidence
관련 다른 성분: 크론병
커큐민 다른 건강 상태에 대한 근거
References
- [1] Mohammad Shehab et al.. Inflamm Bowel Dis. 2026. Comparative Efficacy of Medical Therapies in Reducing the Risk of Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network … doi:10.1093/ibd/izaf186 PubMed
- [2] Saeid Mohseni et al.. Front Nutr. 2025. Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials. doi:10.3389/fnut.2025.1494351 PubMed
- [3] Sandra Utz et al.. Z Gastroenterol. 2024. [Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review]. doi:10.1055/a-2279-5045 PubMed
- [4] Zi-Wen Meng et al.. World J Gastroenterol. 2024. Use of curcumin and its nanopreparations in the treatment of inflammatory bowel disease. doi:10.3748/wjg.v30.i3.280 PubMed
- [5] Lucas Fornari Laurindo et al.. Metabolites. 2023. Phytochemicals and Regulation of NF-kB in Inflammatory Bowel Diseases: An Overview of In Vitro and In Vivo Effects. doi:10.3390/metabo13010096 PubMed
- [6] Liuting Zeng et al.. Front Immunol. 2022. Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune Diseases: A Systematic Review and Meta-Analysis of … doi:10.3389/fimmu.2022.896476 PubMed
- [7] Hui-Fang Chiu et al.. Molecules. 2021. Gastroprotective Effects of Polyphenols against Various Gastro-Intestinal Disorders: A Mini-Review with Special Focus on Clinical Evidence. doi:10.3390/molecules26072090 PubMed
- [8] Ricardo de Alvares Goulart et al.. J Med Food. 2021. Effects of the Use of Curcumin on Ulcerative Colitis and Crohn's Disease: A Systematic Review. doi:10.1089/jmf.2020.0129 PubMed
- [9] Anthony Buisson et al.. United European Gastroenterol J. 2021. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. doi:10.1002/ueg2.12068 PubMed
- [10] Justyna Kikut et al.. Eur J Nutr. 2021. Diet supporting therapy for inflammatory bowel diseases. doi:10.1007/s00394-021-02489-0 PubMed
- [11] Masoumeh Atefi et al.. Adv Exp Med Biol. 2021. A Systematic Review of the Clinical Use of Curcumin for the Management of Gastrointestinal Diseases. doi:10.1007/978-3-030-56153-6_18 PubMed
- [12] Ken Sugimoto et al.. J Crohns Colitis. 2020. Highly Bioavailable Curcumin Derivative Ameliorates Crohn's Disease Symptoms: A Randomized, Double-Blind, Multicenter Study. doi:10.1093/ecco-jcc/jjaa097 PubMed
- [13] Gilles Bommelaer et al.. Clin Gastroenterol Hepatol. 2020. Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial. doi:10.1016/j.cgh.2019.08.041 PubMed
- [14] Mariana Roque Coelho et al.. Nutrients. 2020. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials. doi:10.3390/nu12082296 PubMed
- [15] Bartosz Malinowski et al.. Nutrients. 2020. The Rundown of Dietary Supplements and Their Effects on Inflammatory Bowel Disease-A Review. doi:10.3390/nu12051423 PubMed
- [16] Mathilde Boube et al.. Dig Liver Dis. 2020. Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in … doi:10.1016/j.dld.2020.03.020 PubMed
- [17] Zhenhuan Yang et al.. Medicine (Baltimore). 2020. The effectiveness and safety of curcumin as a complementary therapy in inflammatory bowel disease: A protocol of systematic review and … doi:10.1097/MD.0000000000022916 PubMed
- [18] Kathryn Burge et al.. Int J Mol Sci. 2019. Curcumin and Intestinal Inflammatory Diseases: Molecular Mechanisms of Protection. doi:10.3390/ijms20081912 PubMed
- [19] Fernando Cunha Neto et al.. Crit Rev Food Sci Nutr. 2019. Curcuminoids from Curcuma Longa: New adjuvants for the treatment of crohn's disease and ulcerative colitis? doi:10.1080/10408398.2018.1456403 PubMed
- [20] Tanyaporn Kaenkumchorn et al.. J Med Food. 2019. Dietary Management of Pediatric Inflammatory Bowel Disease. doi:10.1089/jmf.2019.0063 PubMed
- [21] Ron Shaoul et al.. Curr Opin Gastroenterol. 2019. Nutritional regulators of intestinal inflammation. doi:10.1097/MOG.0000000000000585 PubMed
- [22] Berkeley N Limketkai et al.. Gastroenterol Clin North Am. 2018. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. doi:10.1016/j.gtc.2017.09.007 PubMed
- [23] Xusheng Xie et al.. Macromol Biosci. 2018. Silk Fibroin-Based Fibrous Anal Fistula Plug with Drug Delivery Function. doi:10.1002/mabi.201700384 PubMed
- [24] James D Lewis et al.. Gastroenterology. 2017. Diet as a Trigger or Therapy for Inflammatory Bowel Diseases. doi:10.1053/j.gastro.2016.10.019 PubMed
- [25] Islam Khan et al.. Med Princ Pract. 2017. Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal. doi:10.1159/000468988 PubMed
- [26] Moftah H Alhagamhmad et al.. JPEN J Parenter Enteral Nutr. 2017. Exploring and Enhancing the Anti-Inflammatory Properties of Polymeric Formula. doi:10.1177/0148607115625627 PubMed
- [27] Allaire Schneider et al.. Complement Ther Med. 2017. Comparison of remicade to curcumin for the treatment of Crohn's disease: A systematic review. doi:10.1016/j.ctim.2017.06.002 PubMed
- [28] Joshua Korzenik et al.. Med Clin North Am. 2017. Complementary and Integrative Gastroenterology. doi:10.1016/j.mcna.2017.04.009 PubMed
- [29] Christian Lodberg Hvas et al.. Ugeskr Laeger. 2017. [Nutrition and dietary supplement in chronic inflammatory bowel diesease]. PubMed
- [30] Alyssa Parian et al.. Curr Pharm Des. 2016. Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis. doi:10.2174/1381612822666151112145033 PubMed
- [31] J Langhorst et al.. J Crohns Colitis. 2015. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. doi:10.1093/ecco-jcc/jju007 PubMed
- [32] Aikaterini Triantafyllidi et al.. Ann Gastroenterol. 2015. Herbal and plant therapy in patients with inflammatory bowel disease. PubMed
- [33] Liza Vecchi Brumatti et al.. Molecules. 2014. Curcumin and inflammatory bowel disease: potential and limits of innovative treatments. doi:10.3390/molecules191221127 PubMed
- [34] Filippo Fontani et al.. Exp Cell Res. 2014. Redox regulation of MMP-3/TIMP-1 ratio in intestinal myofibroblasts: effect of N-acetylcysteine and curcumin. doi:10.1016/j.yexcr.2014.02.019 PubMed
- [35] Subash C Gupta et al.. AAPS J. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. doi:10.1208/s12248-012-9432-8 PubMed
- [36] S C Ng et al.. Aliment Pharmacol Ther. 2013. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. doi:10.1111/apt.12464 PubMed
- [37] David L Suskind et al.. J Pediatr Gastroenterol Nutr. 2013. Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. doi:10.1097/MPG.0b013e318276977d PubMed
- [38] Kris Nys et al.. Nat Rev Gastroenterol Hepatol. 2013. Autophagy: a new target or an old strategy for the treatment of Crohn's disease? doi:10.1038/nrgastro.2013.66 PubMed
- [39] Manjeshwar Shrinath Baliga et al.. Food Funct. 2012. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations. doi:10.1039/c2fo30097d PubMed
- [40] Alfred E Slonim et al.. J Am Coll Nutr. 2009. Effect of exclusion diet with nutraceutical therapy in juvenile Crohn's disease. doi:10.1080/07315724.2009.10719782 PubMed
- [41] William P Steward et al.. Mol Nutr Food Res. 2008. Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research. doi:10.1002/mnfr.200700148 PubMed
- [42] F J Bosques-Padilla et al.. Rev Gastroenterol Mex. 2008. [Current concepts about the treatment of inflammatory bowel disease, biological therapy]. PubMed
- [43] Peter R Holt et al.. Dig Dis Sci. 2005. Curcumin therapy in inflammatory bowel disease: a pilot study. doi:10.1007/s10620-005-3032-8 PubMed
- [44] Padmini Srinivasan et al.. Bioinformatics. 2004. Mining MEDLINE for implicit links between dietary substances and diseases. doi:10.1093/bioinformatics/bth914 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.